Lead Clinical Laboratory Scientist (CLS), Oncology at BillionToOne

Menlo Park, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Healthcare, OncologyIndustries

Requirements

California Clinical Laboratory Scientist License
Lead clinical laboratory daily supervision in alignment with company values and mission

Responsibilities

Hold General Supervisor delegation
Oversee end-to-end processing of cancer blood samples in a high complexity, high-growth CLIA setting
Support the Northstar Oncology product

Skills

Key technologies and capabilities for this role

California CLS LicenseCLIAGeneral Supervisor DelegationCancer Blood Sample ProcessingLaboratory SupervisionMolecular DiagnosticsLiquid BiopsyCell-free DNAHigh Complexity LabOncology Testing

Questions & Answers

Common questions about this position

Is this position remote or onsite?

This is an onsite position.

What is the salary for this Lead Clinical Laboratory Scientist role?

This information is not specified in the job description.

What are the key requirements for this position?

Candidates must have a California Clinical Laboratory Scientist License and experience leading clinical laboratory daily supervision in alignment with company values and mission.

What does the company culture look like at BillionToOne?

BillionToOne has been recognized by Forbes as one of America's Best Startup Employers for 2024, highlighting its exceptional work environment and commitment to innovation.

How do I apply for this Lead CLS position?

Visit www.billiontoone.com for more detailed information about BillionToOne and its groundbreaking work.

BillionToOne

Molecular diagnostics for prenatal and oncology testing

About BillionToOne

BillionToOne specializes in molecular diagnostics within the healthcare sector, focusing on prenatal screening and oncology testing. Their proprietary QCT technology allows for the detection and quantification of diseases at a single base-pair resolution, enabling the identification of minute variations in DNA. The company offers two main products: Northstar Select™, which helps determine the best initial therapy for patients, and Northstar Response™, which tracks the effectiveness of that therapy. Unlike many competitors, BillionToOne emphasizes accuracy, efficiency, and accessibility in molecular testing, providing diagnostic services directly to healthcare providers. Their goal is to positively impact healthcare by making molecular testing more reliable and available to everyone.

Menlo Park, CaliforniaHeadquarters

2016Year Founded

$380.2MTotal Funding

SERIES_DCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Competitive pay

Retirement savings package

Parental leave

Free snacks & lunches

Medical, dental, & vision premiums

On campus perks

Free-on-site EV charging

Risks

Emerging biotech startups could threaten BillionToOne's market share.

Rapid technological advancements may render their current technology obsolete.

Expansion into new facilities may face operational challenges or delays.

Differentiation

BillionToOne's QCT technology detects DNA variations at single base-pair resolution.

Their UNITY Fetal Antigen NIPT is the first US cfDNA test for fetal antigen genotyping.

They replace invasive amniocentesis with a safe, affordable blood test for prenatal screening.

Upsides

BillionToOne achieved a billion-dollar valuation with a $130 million funding round.

Their new Austin facility will create 1,000 jobs, boosting production and local economy.

Recognition as Diagnostics Company of the Year highlights their industry leadership.

Land your dream remote job 3x faster with AI

Try Jobo Free